| Name | Title | Contact Details |
|---|
Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.
Nuvelo, Inc. is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BGI Americas Corporation is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.
Exothera is a CDMO delivering customized process development and GMP production services for viral vectors in Belgium